Abstract | BACKGROUND: Cardiac and hepatic magnetic resonance imaging evaluation during treatment can tailor physicians' chelation therapy titrations. AIM: The aim of the study was to assess the relationship of cardiac and hepatic T2* values with chelation therapy in patients with transfusion-dependent thalassemia (TDT). METHODS: A total of 106 patients with TDT who were followed up in Istanbul Medical Faculty Thalassemia Center were evaluated for the study. Forty-eight (45%) patients with TDT had more than one consecutive MRI examination. The patients were divided into three subgroups according to the cardiac T2* values as the high-risk group (T2* MRI < 10 ms), medium-risk group (T2* MRI 10-20 ms), and the low-risk group (T2* MRI > 20 ms). RESULTS: The majority of patients used DFX ( deferasirox) (79%) and deferiprone ( DFP) (17%). Approximately 80% of patients according to cardiac T2* value and 40% of patients according to hepatic T2* value were initially in the low-risk group. Patients with follow-up MRI examinations exhibited significant improvement in liver iron concentration, which correlated with an increase in hepatic T2* values. The decrease of liver iron concentration was prominent in the DFX group (p < 0.01). The serum ferritin level was significantly correlated with liver iron concentrations (rs = 0.65, p < 0.001), hepatic T2* value (rs = - 0.62, p < 0.001), but not with cardiac T2* value (rs = - 0.20, p = 0.07). CONCLUSION: Cardiovascular and hepatic MRI is a useful follow-up tool during the assessment of risk groups and chelation therapy of patients with TDT. Consecutive MRI tests showed good monitoring of cardiac and liver iron overload.
|
Authors | Zeynep Karakas, Yasin Yilmaz, Zuhal Bayramoglu, Serap Karaman, Selime Aydogdu, Ayse Ozkan Karagenc, Deniz Tugcu, Memduh Dursun |
Journal | La Radiologia medica
(Radiol Med)
Vol. 123
Issue 8
Pg. 572-576
(Aug 2018)
ISSN: 1826-6983 [Electronic] Italy |
PMID | 29663188
(Publication Type: Journal Article)
|
Chemical References |
- Benzoates
- Iron Chelating Agents
- Pyridones
- Triazoles
- Deferiprone
- Deferasirox
|
Topics |
- Adolescent
- Adult
- Benzoates
(therapeutic use)
- Blood Component Transfusion
- Chelation Therapy
(methods)
- Child
- Deferasirox
- Deferiprone
- Female
- Humans
- Iron Chelating Agents
(therapeutic use)
- Iron Overload
(diagnostic imaging, drug therapy)
- Liver
(metabolism)
- Magnetic Resonance Imaging
(methods)
- Male
- Middle Aged
- Myocardium
(metabolism)
- Pyridones
(therapeutic use)
- Retrospective Studies
- Thalassemia
(therapy)
- Treatment Outcome
- Triazoles
(therapeutic use)
- Turkey
|